Switching to BIC/FTC/TAF or Long-Acting ART in Viremic Patients: Real-World Data

Switching to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) is a safe and effective regimen-optimization strategy for adults with HIV who are already virologically suppressed on antiretroviral therapy, according to study findings published in Infectious Diseases and Therapy. Concurrently, real-world data published in Clinical Infectious Diseases support the use of long-acting antiretroviral therapy for people with HIV, including patients who present with viremia at initiation.

Real-World Data Support BIC/FTC/TAF Regimen Optimization

For adults living with HIV who have already achieved virologic suppression, optimizing current treatment regimens remains a priority for clinicians aiming to reduce pill burden and manage long-term tolerability. Recent findings published in Infectious Diseases and Therapy indicate that transitioning patients to bictegravir plus emtricitabine and tenofovir alafenamide, commonly known as BIC/FTC/TAF, functions as both a safe and effective regimen-optimization strategy.

Long-Acting Antiretroviral Therapy in Viremic Patients

According to study findings published in Clinical Infectious Diseases, real-world data now support the use of long-acting antiretroviral therapy (ART) even among individuals who are viremic when they initiate treatment.

Evaluating Treatment Efficacy Across Patient Populations

While the Infectious Diseases and Therapy study focuses on virologically suppressed adults transitioning to oral BIC/FTC/TAF, the Clinical Infectious Diseases research expands the utility of long-acting modalities toward viremic starters.

Frequently Asked Questions

What is BIC/FTC/TAF?

BIC/FTC/TAF is a fixed-dose combination antiretroviral therapy consisting of bictegravir, emtricitabine, and tenofovir alafenamide, prescribed to treat HIV.

Can long-acting ART be used if a patient has viremia?

Yes, according to study findings published in Clinical Infectious Diseases, real-world data support the use of long-acting antiretroviral therapy for people with HIV, including individuals who are viremic at initiation.

Is switching to BIC/FTC/TAF safe for suppressed adults?

Research published in Infectious Diseases and Therapy indicates that switching to BIC/FTC/TAF is a safe and effective regimen-optimization strategy for adults with HIV who are already virologically suppressed.

Stay Informed: To keep up-to-date with the latest clinical findings in infectious disease management and antiretroviral therapy, explore our HIV Treatment Archives or subscribe to our professional clinical updates.